One Lambda, Inc.

One Lambda, Inc., a subsidiary of Thermo Electron Corporation headquartered in Canoga Park, California, manufactures human leukocyte antigen (HLA) typing reagents, antibody screening kits, laboratory instrumentation, and diagnostic supplies for federal healthcare and research institutions as a prime contractor competing in full-and-open procurements with no set-aside designations. The company operates across 350 federal awards spanning nineteen years, with a combined potential value of $87.1 million and $48.7 million in obligated dollars; recent activity shows five awards per year in 2025 and 2026, with a recompete cliff of $1.4 million in the next twenty-four months.

One Lambda's customer base concentrates in federal military and veteran healthcare. The Defense Health Agency (27 awards, $26.4 million), Veterans Integrated Service Network 23 (44 awards, $22.9 million), and the Navy Bureau of Medicine and Surgery (55 awards, $21.7 million) together account for approximately 51% of awards and 95% of combined potential value. The NIH Clinical Center (15 awards, $10.1 million) and Veterans Integrated Service Network 9 (36 awards, $1.6 million) round out the top five; a stark divergence exists between award count and dollar value, with BUMED placing the most orders at lower individual deal sizes while DHA and VISN 23 anchor the largest single contracts. One Lambda holds two master ordering vehicles: a single-award $6.9 million Indefinite Delivery Contract with VISN 23 running through September 30, 2030, and a $7.5 million single-award Blanket Purchase Agreement with DHA running through December 8, 2029. Additional vehicles include BPA HT001415A0049 (11 task orders, $2.2 million), BPA HT001420A0015 (9 task orders, $2.6 million), and IDC 75N90020D00022 (5 task orders, $3.3 million).

Capability work centers on immunogenetic and transplant diagnostic products. Representative contracts include a $1.26 million delivery order with VISN 23 (October 2025, first ordering period under the new IDIQ for HLA reagents), a $615,447 purchase order with the NIH Clinical Center (June 2026, HLA typing and antibody screening reagents for the HLA Lab), an $847,379 BPA call with DHA (February 2026, organ transplant supplies under the $7.5 million master BPA), and a $324,901 purchase order with VISN 23 (September 2026, HLA Pro Primary automation equipment and installation at Iowa City VA). One Lambda also supplies HistoTrac laboratory information system maintenance and software updates across federal facilities; NAICS concentration shows 94 awards in Research and Development in Biotechnology, 49 in In-Vitro Diagnostic Substance Manufacturing, and 11 in Analytical Laboratory Instrument Manufacturing, with primary PSC categories being Laboratory Equipment and Supplies (195 awards) and Medical and Surgical Instruments, Equipment, and Supplies (69 awards).

One Lambda operates as a 100% prime footprint with no subcontracting in the federal award record and competes entirely in unrestricted procurements; the company does not hold SBA set-aside designations and wins work on sole-source and competitive open bases grounded in technical compatibility with existing federal laboratory systems and reagent supply chains.